rAAV Ocular Gene Therapy for CNGA3, CNGB3, and REP-1 Restoration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Choroideremia and achromatopsia are retinal diseases characterized by progressive vision loss due to defects in Rab Escort Protein-1 (REP-1) and cyclic nucleotide-gated channel proteins, respectively, for which effective gene therapy compositions are needed to restore protein function.
Innovation Solution
Development of codon-optimized cDNA sequences encoding REP-1 and CNGA3/CNGB3, packaged in recombinant adeno-associated virus (rAAV) vectors, to enhance protein expression and correct defects in retinal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gene therapy compositions are developed to restore protein function in retinal diseases, then protein expression and cellular function are improved, but the complexity of the treatment and manufacturing process increases
Solution Approach 1:
The gene therapy composition is segmented into distinct functional components: rAAV vector particles containing the therapeutic nucleic acid sequence, separate from packaging cells and other manufacturing components. This segmentation allows for standardized vector production while managing the overall system complexity.
Solution Approach 2:
Recombinant adeno-associated virus (rAAV) vectors serve as intermediaries that deliver the therapeutic nucleic acid sequences (encoding REP-1, CNGA3, or CNGB3) to target retinal cells. The rAAV vector acts as a mediator between the genetic material and the diseased cells, simplifying the delivery mechanism while achieving reliable protein restoration.
2Productivity
If codon-optimized cDNA sequences are used to enhance protein expression, then protein production efficiency is improved, but the manufacturing precision and optimization process become more complex
Solution Approach 1:
The nucleic acid sequences are codon-optimized by changing the codon parameters to match the preferred codon usage of human cells. This parameter optimization enhances translation efficiency and protein expression levels without altering the amino acid sequence, thereby improving productivity while maintaining manufacturing feasibility through well-established molecular biology techniques.
3Reliability
If rAAV vectors are used to deliver therapeutic genes, then gene delivery efficiency to retinal cells is improved, but the vector production and quality control processes become more complex
Solution Approach 1:
The rAAV vector system is designed to self-assemble and self-deliver the therapeutic nucleic acid sequences to target retinal cells. The viral particles naturally infect retinal photoreceptors and deliver the transgene, leveraging the virus's inherent biological mechanisms to achieve efficient gene delivery without requiring complex external delivery systems.
Data Source
AI summary
Compositions and methods are provided for treating ocular disorders in a subject are provided. In one aspect, an adeno-associated viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding CNGA3. In another aspect, an adeno-associated viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding CNGB3. In another aspect, an adeno-associated viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding REP-1. In desired embodiments, the subject is human, cat, dog, sheep, or non-human primate.